Jupiter Neurosciences To Acquire U.S. Licensing Rights To ALA-002 From Pharmala Biotech For $3.33M, Comprising $1.5M In Cash And $1.83M Of JUNS Stock

Benzinga Newsdesk www.benzinga.com Neutral 79.9%